FDA Accepts ANDA for Leucovorin Calcium by Ingenus Pharmaceuticals
The FDA has accepted the Abbreviated New Drug Application (ANDA) for Leucovorin Calcium submitted by Ingenus Pharmaceuticals.
Company
Ingenus Pharmaceuticals
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The FDA's acceptance of Ingenus Pharmaceuticals' ANDA for Leucovorin Calcium signifies a potential shift in the oncology supportive care market, increasing competition against existing branded products. Portfolio teams must evaluate the implications for market share and pricing strategies as this generic product approaches market entry.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor the timeline for final approval and market entry of Ingenus' Leucovorin Calcium.
Related companies & assets
Companies
Assets
Sources & Humanexa intelligence
Related Humanexa pages
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.